Myeloid disease: Edited by Martin S. TallmanCore binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?Dombret, Hervéa; Preudhomme, Claudeb; Boissel, NicolasaAuthor Information aDepartment of Hematology, Hôpital Saint-Louis (AP-HP), Paris, France bLaboratory of Hematology, Hôpital Claude Hurriez, CHRU Lille, France Correspondence to Professor Hervé Dombret, Hôpital Saint-Louis (AP-HP), University Paris 7 – Institut Universitaire d'Hematologie, 1 Avenue Claude Vellefaux, 75010 Paris, France Tel: +33 1 4249 9643; fax: +33 1 4249 9345; e-mail: [email protected] Current Opinion in Hematology: March 2009 - Volume 16 - Issue 2 - p 92-97 doi: 10.1097/MOH.0b013e3283257b18 Buy Metrics Abstract Purpose of review Core binding factor acute myeloid leukemia (CBF-AML) corresponds to two distinct subtypes of AML characterized by recurrent favorable chromosome translocations, namely t(8;21) and inv(16)/t(16;16). Given the relatively good outcome of patients with CBF-AML, when treated with intensive chemotherapy including high-dose cytarabine, they are generally not considered as candidates for intensification with allogeneic stem cell transplantation in the first complete remission. The optimal treatment strategy (place of stem cell transplantation, best postremission chemotherapy, role of targeted agents) remains, however, to be defined in these patients. Recent findings The biological and prognostic heterogeneity of both CBF-AML subtypes, including gene mutation and gene expression profiles as well as molecular response to therapy, has been recently described. Summary These new insights in the heterogeneity of CBF-AML suggest that a tailored approach might be preferred to a unique predefined strategy to treat these patients. © 2009 Lippincott Williams & Wilkins, Inc.